Wedbush Reaffirms Outperform Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a report issued on Monday, RTT News reports. They currently have a $37.00 price target on the stock. Wedbush’s target price suggests a potential upside of 111.19% from the company’s current price.

Several other research firms have also recently weighed in on KURA. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Thursday, October 24th. UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $17.52 on Monday. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $18.95 and a 200 day moving average price of $20.02. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -7.86 and a beta of 0.86. Kura Oncology has a twelve month low of $8.17 and a twelve month high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. Kura Oncology’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the company posted ($0.53) earnings per share. Research analysts predict that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently made changes to their positions in KURA. nVerses Capital LLC bought a new stake in Kura Oncology during the 3rd quarter worth approximately $25,000. ProShare Advisors LLC grew its holdings in shares of Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares during the last quarter. Aaron Wealth Advisors LLC increased its stake in shares of Kura Oncology by 2.4% in the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after buying an additional 1,673 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC raised its holdings in shares of Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after buying an additional 2,167 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.